Clinical trial · Interventional
Impact of Web Application Support Versus Standard Management on Compliance With Adjuvant Hormone Therapy at 18 Months in Patients Treated for Breast Cancer
NCT04554927CI-TRIAL-00111865WEBAPPACactive not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators hypothesize that the implementation of a Web-application in patients initiating adjuvant hormone therapy for breast cancer brings a benefit on treatment adherence and quality of life.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Hormono Therapy | — | UNRESOLVED | — |
| Web-application | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Standard accompaniment | Other | — | UNRESOLVED |
| WEB-Application | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- WEB-application
- interventionNames
- Other: WEB-Application
- type
- ACTIVE_COMPARATOR
- label
- Standard accompaniment
- interventionNames
- Other: Standard accompaniment
Primary outcomes (1)
- measure
- Observance of hormontherapy
- timeFrame
- 18 months
- description
- Evaluate the benefit of a web-based application on hormone therapy compliance (Morisky questionnary; answer Yes or No; 8 questions)
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient \> 18 years old * Breast cancer patient candidate for adjuvant hormone therapy * Mastery of the French language * Patient with a cell phone and an Internet connection * Patient able to use a computer, smartphone, or tablet. * Patient affiliated to a social security system * Signing of informed consent prior to any specific study-related procedure Exclusion Criteria: * Patient who has previously received hormone therapy for cancer. * Patient not trained in the use of the application * Any associated medical or psychiatric condition that might compromise the patient's ability to participate in the study * Patients with locoregional or metastatic recurrence * Other history of cancer. * Patient deprived of liberty, under guardianship or curatorship * Simultaneous participation in a therapeutic clinical trial or other clinical study involving a connected tool * Patient unable to undergo trial follow-up for geographical, social or psychopathological reasons
References
Publications (1)
- DERIVEDGernier F, Grellard JM, Dupont C, Castel H, Fernette M, Lahaye F, Charles RM, Leroux T, Ory C, Faveyrial A, Morel A, Emile G, Levy C, Segura C, Allouache D, Johnson A, Geffrelot J, Gunzer K, Lelaidier A, Girault G, Dubot-Poitelon C, San C, Lequesne J, Clarisse B. Impact of web application support versus standard management on adherence with adjuvant hormone therapy in patients treated for breast cancer: the WEBAPPAC study. BMC Cancer. 2023 Aug 9;23(1):736. doi: 10.1186/s12885-023-11242-1. PMID 37559004